MedPath

Tagged News

FLOT Perioperative Chemotherapy Extends Survival Over CROSS Protocol in Esophageal Cancer

Oncology
  • The phase 3 ESOPEC trial demonstrated that perioperative chemotherapy with FLOT significantly improved overall survival compared to neoadjuvant chemoradiation with CROSS in patients with locally advanced esophageal adenocarcinoma.
  • Patients receiving FLOT achieved a median overall survival of 66 months versus 37 months with CROSS, representing a 30% reduction in death risk with statistical significance.
  • The study enrolled 438 patients across 25 German centers and showed FLOT also improved progression-free survival and pathological complete response rates.
  • These findings may establish FLOT as the new standard of care for locally advanced esophageal cancer, though immunotherapy combinations are emerging as additional treatment options.

NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)

NCT01726452CompletedPhase 3
Cancer Trials Ireland
Posted 1/24/2013

Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus

NCT02509286Active, Not RecruitingPhase 3
University Hospital Schleswig-Holstein
Posted 1/1/2016

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer

NCT02743494Active, Not RecruitingPhase 3
Bristol-Myers Squibb
Posted 7/14/2016

Global Breast Cancer Therapeutics Market Expected to Reach $78.61 Billion by 2033

OncologyTargeted TherapyMonoclonal AntibodyAIPrecision MedicineDrug Approval
• The global breast cancer therapeutics market, valued at $32.93 billion in 2023, is projected to reach $78.61 billion by 2033, growing at a CAGR of 9.09% over the next decade.
• North America dominates the market with a 38.61% revenue share, driven by high breast cancer prevalence and presence of key pharmaceutical companies including Pfizer, Roche, and Novartis.
• Targeted therapies hold the largest market segment at 64.85%, with hormone receptor-positive treatments accounting for 66.97% of the market as precision medicine approaches gain traction.

NIH's Novel Five-Drug Combination Shows Promise for Relapsed Aggressive B-Cell Lymphoma

Targeted TherapyOncologyMonoclonal Antibody
  • NIH researchers have developed ViPOR, a non-chemotherapy five-drug regimen that achieved complete remission in 38% of patients with relapsed or refractory diffuse large B-cell lymphoma.
  • The treatment was particularly effective in two specific subtypes: non-GCB DLBCL (62% complete response) and double-hit GCB DLBCL (53% complete response), offering new hope for patients with limited options.
  • At the two-year mark, 36% of all treated patients were still alive and 34% remained disease-free, with some maintaining remission beyond four years despite previously facing poor prognoses.

Roche's Columvi Demonstrates 41% Reduction in Death Risk in Phase III DLBCL Trial

OncologyDrug Approval
  • Roche's Phase III STARGLO study showed Columvi plus chemotherapy reduced death risk by 41% versus rituximab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma patients.
  • The combination achieved a median overall survival of 25.5 months compared to 12.9 months for the control arm, with complete response rates of 58.5% versus 25.3%.
  • Results position Columvi as the first CD20xCD3 bispecific antibody to demonstrate survival benefit in DLBCL in a randomized Phase III trial.
  • The data will be submitted to global health authorities including FDA and EMA to support conversion from accelerated to full approval.

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04408638Active, Not RecruitingPhase 3
Hoffmann-La Roche
Posted 2/23/2021

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080RecruitingPhase 3
Hoffmann-La Roche
Posted 9/18/2023

Liso-Cel CAR-T Therapy Shows Promising Results Across Multiple Lymphoma Subtypes

CAR-TOncology
  • Lisocabtagene maraleucel (liso-cel) demonstrates clinically meaningful activity across various lymphoma subgroups, including mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.
  • In relapsed/refractory mantle cell lymphoma patients, liso-cel achieved a median overall survival of 13.5 months and progression-free survival of 7.4 months despite heavy pretreatment.
  • Follicular lymphoma patients show particularly stellar response rates with durable complete remissions lasting nearly 3 years of follow-up.
  • Experts advocate for exploring liso-cel use in earlier treatment lines, particularly for high-risk patient subgroups who may benefit from better-preserved T-cell health.

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

NCT03575351CompletedPhase 3
Celgene
Posted 10/23/2018

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

NCT02631044CompletedPhase 1
Juno Therapeutics, a Subsidiary of Celgene
Posted 1/6/2016

Can-Fite Receives IRB Approval for Phase IIa Pancreatic Cancer Trial of Namodenoson

Orphan DrugOncology
  • Can-Fite BioPharma received Institutional Review Board approval from Rabin Medical Center to initiate a Phase IIa open-label study evaluating Namodenoson in advanced pancreatic adenocarcinoma patients.
  • The multicenter trial will enroll approximately 20 patients with disease progression on first-line therapy, administering oral Namodenoson 25 mg twice daily in 28-day cycles.
  • Namodenoson demonstrated efficacy in preclinical pancreatic cancer models through deregulation of Wnt/β-catenin, NF-κB, and RAS signaling pathways.
  • The A3 adenosine receptor-targeting drug has shown promising results in liver cancer, with one patient achieving complete response lasting over 7 years.

Namodenoson Treatment of Advanced Pancreatic Cancer

NCT06387342RecruitingPhase 2
Can-Fite BioPharma
Posted 11/10/2024

CARsgen's Satri-cel Shows Promise in Phase 1 Trial for Gastrointestinal Cancers

CAR-TOncology
  • Final results from the Phase 1 trial of satricabtagene autoleucel (satri-cel) demonstrate promising efficacy and manageable safety in patients with Claudin18.2-positive advanced gastrointestinal cancers, particularly gastric and gastroesophageal junction cancers.
  • The groundbreaking CAR T-cell therapy targeting Claudin18.2 represents a significant advancement in solid tumor treatment, with results simultaneously published in Nature Medicine and presented at the 2024 ASCO Annual Meeting.
  • Satri-cel has received multiple regulatory designations including RMAT designation from the FDA and PRIME eligibility from the EMA, positioning it as a potential first-in-class therapy globally for Claudin18.2-positive solid tumors.

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

NCT04581473Active, Not RecruitingPhase 1
CARsgen Therapeutics Co., Ltd.
Posted 10/23/2020

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

NCT05911217RecruitingPhase 1
CARsgen Therapeutics Co., Ltd.
Posted 7/11/2023

Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

NCT04404595Active, Not RecruitingPhase 1
CARsgen Therapeutics Co., Ltd.
Posted 10/23/2020

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

NCT03874897CompletedPhase 1
Peking University
Posted 3/26/2019

New Trial Data Shows Enhertu Reduces Breast Cancer Progression Risk by 38% as Access Remains Denied in England

Targeted TherapyOncology
  • New trial results from the Destiny-Breast06 study show Enhertu reduced the risk of HER2-low breast cancer progression by 38% compared to standard chemotherapy, with patients living without disease progression for 13.2 months versus 8.1 months.
  • The drug demonstrated superior efficacy with 60% of patients responding to treatment compared to 30% with chemotherapy, building on previous studies showing overall survival improvements of over six months.
  • Despite compelling clinical evidence, approximately 1,000 women annually in England and Wales are denied access to Enhertu due to NICE's cost-effectiveness concerns, while the drug remains available in Scotland and 13 other European countries.
  • Patient advocates and charities describe the access disparity as "utterly unacceptable," with ongoing negotiations between NICE, NHS England, and manufacturers Daiichi Sankyo and AstraZeneca to resolve pricing issues.

Bispecific Antibodies Show Promise in Multiple Myeloma Treatment Across Different Patient Populations

OncologyCAR-TMonoclonal Antibody
  • Talquetamab demonstrated a 71.4% objective response rate and 28.6% complete response rate in heavily pretreated relapsed/refractory multiple myeloma patients, including those with poor functional status and prior CAR-T therapy.
  • The teclistamab combination with daratumumab and lenalidomide achieved a 92.3% overall response rate and 80.8% complete response rate in newly diagnosed multiple myeloma patients ineligible for transplant.
  • Both bispecific antibody treatments showed manageable safety profiles with cytokine release syndrome as the primary toxicity, though infection risk requires careful monitoring and prophylaxis.
  • These findings expand treatment options for multiple myeloma patients across the disease spectrum, from newly diagnosed to heavily pretreated cases.

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222RecruitingPhase 3
Janssen Research & Development, LLC
Posted 10/25/2022

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT03399799Active, Not RecruitingPhase 1
Janssen Research & Development, LLC
Posted 12/16/2017

Novartis Acquires Mariana Oncology for $1 Billion to Strengthen Radioligand Therapy Pipeline

Oncology
  • Novartis announced a $1 billion acquisition of Mariana Oncology with up to $750 million in milestone payments to expand its radioligand therapy capabilities.
  • The deal provides access to Mariana's lead candidate MC-339, an actinium-based radioligand therapy targeting small cell lung cancer currently in preclinical development.
  • Mariana brings specialized radiopharmaceutical manufacturing capabilities and an oncology radio-conjugation platform using both alpha- and beta-emitting radionuclides.
  • The acquisition strengthens Novartis' position in the competitive radioligand therapy space, following similar billion-dollar deals by AstraZeneca, Bristol Myers Squibb, and Eli Lilly.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.